{"entity":{"id":"nct04587830","kind":"trial","name":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","aka":[],"tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Polaris Group, active and no longer recruiting.","summary":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme is a phase 2 interventional study registered as NCT04587830 by Polaris Group, with 100 participants enrolled, started 2020-09-14 and due to reach its primary completion in 2027-02-28. Interventions recorded: ADI-PEG 20, Temozolomide and Placebo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04587830","url":"https://clinicaltrials.gov/study/NCT04587830"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":["polaris-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04587830","phase":"2","setting":"Phase 1-2 Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme (GBM)","sponsor":"Polaris Group","enrolled":100,"outcomes":[]},"route":"/trials/nct04587830/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"polaris-group","kind":"company","name":"Polaris Group","route":"/companies/polaris-group/"}]}}